Brief: Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing
20/03/2026 21:43
March 20 (Reuters) - SEC Filing: REGENXBIO INC - ENTERS SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE ON MARCH 18, 2026 - SEC FILING REGENXBIO INC - TO PAY $10.0 MILLION TO GLAXOSMITHKLINE FOR ALLEGED UNDERPAYMENT OF SUBLICENSE FEES - SEC FILING REGENXBIO INC - SETTLEMENT AGREEMENT INCLUDES MUTUAL RELEASES OF PAST AND CERTAIN FUTURE CLAIMS - SEC FILING REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING Source text: [ID:n0001193125-26-117913] Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))